Radhika Thokala

TL;DR: Methods for generating and biobanking patient-derived glioblastoma organoids (GBOs) that recapitulate the histological features, cellular diversity, gene expression, and mutational profiles of their corresponding parental tumors are reported.

TL;DR: Two humanized interleukin-13 receptor α2 (IL-13Rα2) chimeric antigen receptors (CARs) were generated and recognized, which will help to inform a human clinical trial design for glioblastoma using humanized scFv-based IL-13rα2 targeting CAR T cells.

TL;DR: In this article , a bispecific T cell engager (BiTE) was used to generate new BiTE molecules in a multivalent approach, using a conformation-specific tumor-related EGFR targeting antibody (806) and Hu08, an IL13Rα2-targeting antibody, as the single chain variable fragments.

TL;DR: In this article, an EGFR-specific CAR was generated by fusing monoclonal antibody (mAb) 806 to a 4-1BB co-stimulatory domain.

TL;DR: In this article , the authors developed an approach that combines CAR T cells with inhibitor of apoptosis protein (IAP) antagonists, a new class of small molecules that mediate the degradation of IAPs, to treat GBM.